相关实验视频

Updated: Jun 28, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

在体内通过htsFLT01/MiRGD纳米复合体抑制血管生成

Mohadeseh Khoshandam¹, Zahra-Soheila Soheili¹, Saman Hosseinkhani²

¹Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Translational oncology

|April 30, 2025

概括

一种新的纳米复合物有效地抑制血管生成,减少乳腺癌模型中的瘤生长和转移. 这种向治疗对治疗血管生成依赖性癌症有前途.

科学领域:

在瘤学瘤学.
生物技术是生物技术.
分子生物学分子生物学

背景情况:

血管新生抑制是一种关键的癌症治疗策略,向瘤生长和转移.
需要新的治疗药物来有效地准血管生成途径.
瘤血管生成依赖于特定的分子标记物和信号通路.

研究的目的:

评估htsFLT01/MiRGD纳米复合物的抗血管性潜力.
在临床前癌症模型,特别是乳腺癌中研究这种新型药物的疗效.
阐明纳米复合物的抗血管性作用背后的分子机制.

主要方法:

进行了体外和体内研究,以评估抗血管生成活性.
对瘤组织进行了组织学和分子分析.
血管新生标记物的基因表达水平 (VEGF,VEGFR,CD31) 被量化.

主要成果:

这种htsFLT01/MiRGD纳米复合体在体外和体内显著抑制了血管生成.
瘤组织学分析显示,血管形成减少,组织结构发生变化.
关键的血管生成相关基因表达 (VEGF,VEGFR,CD31) 显著下调.
治疗还诱导了亡并抑制了瘤细胞的增殖.

结论:

该htsFLT01/MiRGD纳米复合体显示出强大的抗血管性活性.
这种药物对血管生成依赖的癌症,包括乳腺癌,具有显著的治疗潜力.
这些发现支持对htsFLT01/MiRGD进行针对性抗血管生成疗法的进一步临床研究.

关键词:

它具有抗血管性作用,具有抗血管性作用.乳腺癌乳腺癌乳腺癌基因治疗是一种基因疗法.在 MiRGDD 里面.htsFLT01 在线观看

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...